Search

Your search keyword '"Conca, Andreas"' showing total 468 results
Start Over Author "Conca, Andreas"
468 results on '"Conca, Andreas"'

2. Relevance of spirituality and perceived social support to mental health of people with pre-existing mental health disorders during the COVID-19 pandemic: a longitudinal investigation

Author

Tutzer, Franziska, Schurr, Timo, Frajo-Apor, Beatrice, Pardeller, Silvia, Plattner, Barbara, Schmit, Anna, Conca, Andreas, Fronthaler, Martin, Haring, Christian, Holzner, Bernhard, Huber, Markus, Marksteiner, Josef, Miller, Carl, Perwanger, Verena, Pycha, Roger, Schmidt, Martin, Sperner-Unterweger, Barbara, and Hofer, Alex

Published
2024
Full Text
View/download PDF

3. Overcoming times of crisis: unveiling coping strategies and mental health in a transnational general population sample during and after the COVID-19 pandemic

Author

Schurr, Timo, Frajo-Apor, Beatrice, Pardeller, Silvia, Plattner, Barbara, Tutzer, Franziska, Schmit, Anna, Conca, Andreas, Fronthaler, Martin, Haring, Christian, Holzner, Bernhard, Huber, Markus, Marksteiner, Josef, Miller, Carl, Perwanger, Verena, Pycha, Roger, Schmidt, Martin, Sperner-Unterweger, Barbara, and Hofer, Alex

Published
2024
Full Text
View/download PDF

6. Stimulationsverfahren in der Kinder- und Jugendpsychiatrie

Author

Grözinger, Michael, Conca, Andreas, Di Pauli, Jan, Nickl-Jockschat, Thomas, Resch, Franz, Section editor, Fegert, Jörg M., Section editor, Plener, Paul L., Section editor, Kaess, Michael, Section editor, Legenbauer, Tanja, Section editor, Döpfner, Manfred, Section editor, Fegert, Jörg M., editor, Resch, Franz, editor, Kaess, Michael, editor, Döpfner, Manfred, editor, Konrad, Kerstin, editor, Legenbauer, Tanja, editor, and Plener, Paul, editor

Published
2024
Full Text
View/download PDF

7. The longitudinal course of psychological distress and resilience in patients with serious mental illnesses during the first two years of the Covid-19 pandemic

Author

Post, Fabienne, Schurr, Timo, Frajo-Apor, Beatrice, Tutzer, Franziska, Schmit, Anna, Plattner, Barbara, Conca, Andreas, Fronthaler, Martin, Haring, Christian, Holzner, Bernhard, Huber, Markus, Marksteiner, Josef, Miller, Carl, Pardeller, Silvia, Perwanger, Verena, Pycha, Roger, Schmidt, Martin, Sperner-Unterweger, Barbara, and Hofer, Alex

Published
2024
Full Text
View/download PDF

12. Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics.

Author

Hart, Xenia Marlene, Gründer, Gerhard, Ansermot, Nicolas, Conca, Andreas, Corruble, Emmanuelle, Crettol, Severine, Cumming, Paul, Frajerman, Ariel, Hefner, Gudrun, Howes, Oliver, Jukic, Marin M., Kim, Euitae, Kim, Seoyoung, Maniscalco, Ignazio, Moriguchi, Sho, Müller, Daniel J., Nakajima, Shinichiro, Osugo, Martin, Paulzen, Michael, and Ruhe, Henricus Gerardus

Subjects
DRUG monitoring, POSITRON emission tomography, DRUG therapy, ESSENTIAL drugs, GLOBAL burden of disease, PHARMACOGENOMICS
Abstract

Background: For psychotic disorders (i.e. schizophrenia), pharmacotherapy plays a key role in controlling acute and long-term symptoms. To find the optimal individual dose and dosage strategy, specialised tools are used. Three tools have been proven useful to personalise drug treatments: therapeutic drug monitoring (TDM) of drug levels, pharmacogenetic testing (PG), and molecular neuroimaging. Methods: In these Guidelines, we provide an in-depth review of pharmacokinetics, pharmacodynamics, and pharmacogenetics for 45 antipsychotics. Over 30 international experts in psychiatry selected studies that have measured drug concentrations in the blood (TDM), gene polymorphisms of enzymes involved in drug metabolism, or receptor/transporter occupancies in the brain (positron emission tomography (PET)). Results: Study results strongly support the use of TDM and the cytochrome P450 (CYP) genotyping and/or phenotyping to guide drug therapies. Evidence-based target ranges are available for titrating drug doses that are often supported by PET findings. Conclusion: All three tools discussed in these Guidelines are essential for drug treatment. TDM goes well beyond typical indications such as unclear compliance and polypharmacy. Despite its enormous potential to optimise treatment effects, minimise side effects and ultimately reduce the global burden of diseases, personalised drug treatment has not yet become the standard of care in psychiatry. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Consequences of the COVID-19 pandemic on admissions to general hospital psychiatric wards in Italy: Reduced psychiatric hospitalizations and increased suicidality

Author

Boldrini, Tommaso, Girardi, Paolo, Clerici, Massimo, Conca, Andreas, Creati, Chiara, Di Cicilia, Giuseppe, Ducci, Giuseppe, Durbano, Federico, Maci, Carlo, Maone, Antonio, Nicolò, Giuseppe, Oasi, Osmano, Percudani, Mauro, Polselli, Gian Marco, Pompili, Maurizio, Rossi, Alessandro, Salcuni, Silvia, Tarallo, Federica, Vita, Antonio, and Lingiardi, Vittorio

Published
2021
Full Text
View/download PDF

18. Guía de consenso de expertos para la monitorización terapéutica de drogas en neuropsicofarmacología

Author

López-Jaramillo, Carlos, Díaz-Zuluaga, Ana M., de Leon, Jose, Schoretsanitis, Georgios, Paulzen, Michael, Unterecker, Stefan, Schwarz, Markus, Conca, Andreas, Zernig, Gerald, Gründer, Gerhard, Haen, Ekkerhard, Baumann, Pierre, Bergemann, Niels, Clement, Hans Willi, Domschke, Katharina, Eckermann, Gabriel, Egberts, Karin, Gerlach, Manfred, Greiner, Christine, Havemann-Reinecke, Ursula, Hefner, Gudrun, Helmer, Renate, Janssen, Ger, Jaquenoud-Sirot, Eveline, Messer, Thomas, Mössner, Rainald, Müller, Matthias J., Pfuhlmann, Bruno, Laux, Gerd, Riederer, Peter, Saria, Alois, Schoppek, Bernd, Silva Gracia, Margarete, Stegmann, Benedikt, Steimer, Werner, Stingl, Julia C., Uhr, Manfred, Ulrich, Sven, Waschgler, Roland, Zurek, Gabriela, and Hiemke, Christoph

Published
2020
Full Text
View/download PDF

20. Long-term impact of resilience and extraversion on psychological distress during the COVID-19 pandemic: a longitudinal investigation among individuals with and without mental health disorders

Author

Schmit, Anna, primary, Schurr, Timo, additional, Frajo-Apor, Beatrice, additional, Pardeller, Silvia, additional, Plattner, Barbara, additional, Tutzer, Franziska, additional, Conca, Andreas, additional, Fronthaler, Martin, additional, Haring, Christian, additional, Holzner, Bernhard, additional, Huber, Markus, additional, Marksteiner, Josef, additional, Miller, Carl, additional, Perwanger, Verena, additional, Pycha, Roger, additional, Schmidt, Martin, additional, Sperner-Unterweger, Barbara, additional, and Hofer, Alex, additional

Published
2024
Full Text
View/download PDF

22. Relevance of spirituality and perceived social support to mental health of people with pre-existing mental health disorders during the COVID-19 pandemic: a longitudinal investigation

Author

Tutzer, Franziska, primary, Schurr, Timo, additional, Frajo-Apor, Beatrice, additional, Pardeller, Silvia, additional, Plattner, Barbara, additional, Schmit, Anna, additional, Conca, Andreas, additional, Fronthaler, Martin, additional, Haring, Christian, additional, Holzner, Bernhard, additional, Huber, Markus, additional, Marksteiner, Josef, additional, Miller, Carl, additional, Perwanger, Verena, additional, Pycha, Roger, additional, Schmidt, Martin, additional, Sperner-Unterweger, Barbara, additional, and Hofer, Alex, additional

Published
2023
Full Text
View/download PDF

24. How Mental Health and Suicidality Changed during the COVID-19 Pandemic: A Longitudinal Study in the General and Psychiatric Population Illustrating Risk and Protective Factors.

Author

Stockner, Mara, Plattner, Barbara, Innamorati, Marco, Hofer, Alex, Burian, Iuliia, Fronthaler, Martin, Giupponi, Giancarlo, Huber, Markus, Macina, Christian, Perwanger, Verena, Pycha, Roger, Schaller, Gerd, and Conca, Andreas

Subjects
COVID-19 pandemic, PROTECTIVE factors, MENTAL health, PSYCHOLOGICAL factors, SUICIDAL ideation, LONELINESS
Abstract

The COVID-19 pandemic has led to an increase in psychological distress in the general population, but contrasting results have been shown regarding its impact on psychological symptoms in clinical and non-clinical samples. Consequently, the aim of the present study was to compare in a longitudinal design (September–November 2020 and February–April 2021) the mental health outcomes of a clinical and a control sample and to determine the implications of various risk and protective factors in this regard. A total of 234 participants from the general population and 80 psychiatric patients took part in the present online study using the following measurements: the Brief Symptom Checklist (BSCL); Three-Item Loneliness Scale (TILS); Resilience Scale-13 (RS-13); and Functional Assessment of Chronic Illness Therapy—Spiritual Well-Being Scale—Non-Illness (FACIT-Sp Non-Illness). The results show an overall decrease in active suicidal ideation as well as "peace", a subscale of spiritual well-being, as well as increases in passive suicidal activation in the clinical sample, which did not change in the control sample. Psychological symptoms did not significantly change in either group. Significant group effects show an increase in resilience in the clinical sample. Resilience and peace turned out to be protective factors for negative mental health outcomes. However, loneliness, which interestingly increased only in the control sample, was shown to be an overall potential risk factor. Our results highlight the complex implications of the COVID-19 pandemic on the mental health outcomes of different groups in the population, demonstrating the necessity of further research, specifically regarding the risk of active and passive suicidal activation. Highlighted protective factors are discussed in regards to spirituality (i.e., peace), which is not strictly related to religion but rather personal spirituality related to the meaning of situations of one's life, as well as in terms of mental health interventions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie: Zusammenfassung der Konsensusleitlinien 2017 der TDM-Arbeitsgruppe der AGNP

Author

Unterecker, Stefan, Hefner, Gudrun, Baumann, Pierre, Gründer, Gerd, Bergemann, Niels, Clement, Hans-Willi, Conca, Andreas, Deckert, Jürgen, Domschke, Katharina, Eckermann, Gabriel, Egberts, Karin, Gerlach, Manfred, Greiner, Christine, Haen, Ekkehard, Havemann-Reinecke, Ursula, Helmer, Renate, Janssen, Ger, Jaquenoud, Eveline, Laux, Gerd, Messer, Thomas, Mössner, Rainald, Müller, Matthias J., Paulzen, Michael, Pfuhlmann, Bruno, Riederer, Peter, Saria, Alois, Schoppek, Bernd, Schoretsanitis, Georgios, Schwarz, Markus, Gracia, Margarethe Silva, Stegmann, Benedikt, Steimer, Werner, Stingl, Julia C., Uhr, Manfred, Ulrich, Sven, Waschgler, Roland, Zernig, Gerald, Zurek, Gabriele, and Hiemke, Christoph

Published
2019
Full Text
View/download PDF

35. Erratum zu: Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie: Zusammenfassung der Konsensusleitlinien 2017 der TDM-Arbeitsgruppe der AGNP

Author

Unterecker, Stefan, Hefner, Gudrun, Baumann, Pierre, Gründer, Gerd, Bergemann, Niels, Clement, Hans-Willi, Conca, Andreas, Deckert, Jürgen, Domschke, Katharina, Eckermann, Gabriel, Egberts, Karin, Gerlach, Manfred, Greiner, Christine, Haen, Ekkehard, Havemann-Reinecke, Ursula, Helmer, Renate, Janssen, Ger, Jaquenoud, Eveline, Laux, Gerd, Messer, Thomas, Mössner, Rainald, Müller, Matthias J., Paulzen, Michael, Pfuhlmann, Bruno, Riederer, Peter, Saria, Alois, Schoppek, Bernd, Schoretsanitis, Georgios, Schwarz, Markus, Gracia, Margarethe Silva, Stegmann, Benedikt, Steimer, Werner, Stingl, Julia C., Uhr, Manfred, Ulrich, Sven, Waschgler, Roland, Zernig, Gerald, Zurek, Gabriele, and Hiemke, Christoph

Published
2019
Full Text
View/download PDF

36. Praktische Durchführung der EKT

Author

Sartorius, Alexander, Pycha, Roger, Grözinger, Michael, Conca, Andreas, Grözinger, Michael, editor, Conca, Andreas, editor, Nickl-Jockschat, Thomas, editor, and Di Pauli, Jan, editor

Published
2013
Full Text
View/download PDF

37. Sicherheits- und Nebenwirkungsprofil der EKT

Author

Kayser, Sarah, Bewernick, Bettina H., Conca, Andreas, Grözinger, Michael, Henkel, Karsten, Prapotnik, Michael, Schläpfer, Thomas E., Grözinger, Michael, editor, Conca, Andreas, editor, Nickl-Jockschat, Thomas, editor, and Di Pauli, Jan, editor

Published
2013
Full Text
View/download PDF

48. Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)

Author

Martinotti, Giovanni, primary, Vita, Antonio, additional, Fagiolini, Andrea, additional, Maina, Giuseppe, additional, Bertolino, Alessandro, additional, Dell'Osso, Bernardo, additional, Siracusano, Alberto, additional, Clerici, Massimo, additional, Bellomo, Antonello, additional, Sani, Gabriele, additional, d'Andrea, Giacomo, additional, Chiaie, Roberto Delle, additional, Conca, Andreas, additional, Barlati, Stefano, additional, Di Lorenzo, Giorgio, additional, De Fazio, Pasquale, additional, De Filippis, Sergio, additional, Nicolò, Giuseppe, additional, Rosso, Gianluca, additional, Valchera, Alessandro, additional, Nucifora, Domenica, additional, Di Mauro, Stefania, additional, Bassetti, Roberta, additional, Martiadis, Vassilis, additional, Olivola, Miriam, additional, Belletti, Sandro, additional, Andriola, Ileana, additional, Di Nicola, Marco, additional, Pettorruso, Mauro, additional, McIntyre, Roger S., additional, and di Giannantonio, Massimo, additional

Published
2022
Full Text
View/download PDF

49. Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations

Author

Schoretsanitis, Georgios, Meyer, Jonathan M., Conca, Andreas, and Hiemke, Christoph

Abstract

Long-acting injectable (LAI) formulations of second-generation antipsychotics (SGA) are a mainstay in the treatment of schizophrenia-spectrum patients, and their use improves adherence and reduces relapse risk. Personalizing LAI-based therapy involves tailoring the transition from oral to LAIs based on individual and drug-related pharmacokinetic peculiarities. We discuss pharmacokinetic considerations as a cornerstone of a smooth transition from oral to LAI SGAs based on works identified using an updated search in PubMed and Embase in February 2023. Establishing the extent of antipsychotic exposure during oral SGA-treatment from the patient’s SGA levels is often a more appropriate orientation method to choose the equivalent LAI dose than population-based data. Oral dose adjustment during LAI transition can also be guided by checking SGA levels before the LAI injection. LAI SGAs may dominate the maintenance treatment of schizophrenia-spectrum disorders with increased use for other severe mental illnesses such as bipolar disorder. Spurring this trend is the development of newer formulations with longer injection intervals and increased administration ease, but transitioning from oral SGA remains a challenge. By understanding the pharmacokinetics of LAI formulations and measuring SGA levels during oral therapy, one can personalize/optimize the switch from oral SGAs to LAI counterparts.

Published
2023
Full Text
View/download PDF

50. Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy

Author

Eichentopf, Luzie, Hiemke, Christoph, Conca, Andreas, Engelmann, Jan B, Gerlach, Manfred, Havemann-Reinecke, Ursula, Hefner, Gudrun, Florio, Vincenzo, Kuzin, Maxim, Lieb, Klaus, Reis, Margareta, Riemer, Thomas G, Serretti, Alessandro, Schoretsanitis, Georgios, Zernig, Gerald, Gründer, Gerhard, Hart, Xenia M, and University of Zurich

Subjects
Allmänmedicin, Psychiatry and Mental health, escitalopram, reference range, blood level, therapeutic drug monitoring, antidepressant response, clinical effects, adverse drug reaction, SERT occupancy, 10054 Clinic for Psychiatry, Psychotherapy, and Psychosomatics, General Practice, 610 Medicine & health
Abstract

IntroductionA titration within a certain therapeutic reference range presupposes a relationship between the blood concentration and the therapeutic effect of a drug. However, this has not been systematically investigated for escitalopram. Furthermore, the recommended reference range disagrees with mean steady state concentrations (11–21 ng/ml) that are expected under the approved dose range (10–20 mg/day). This work systematically investigated the relationships between escitalopram dose, blood levels, clinical effects, and serotonin transporter occupancy.MethodsFollowing our previously published methodology, relevant articles were systematically searched and reviewed for escitalopram.ResultsOf 1,032 articles screened, a total of 30 studies met the eligibility criteria. The included studies investigated escitalopram blood levels in relationship to clinical effects (9 studies) or moderating factors on escitalopram metabolism (12 studies) or serotonin transporter occupancy (9 studies). Overall, the evidence for an escitalopram concentration/effect relationship is low (level C).ConclusionBased on our findings, we propose a target range of 20–40 ng/ml for antidepressant efficacy of escitalopram. In maintenance treatment, therapeutic response is expected, when titrating patients above the lower limit. The lower concentration threshold is strongly supported by findings from neuroimaging studies. The upper limit for escitalopram’s reference range rather reflects a therapeutic maximum than a tolerability threshold, since the incidence of side effects in general is low. Concentrations above 40 ng/ml should not necessarily result in dose reductions in case of good clinical efficacy and tolerability. Dose-related escitalopram concentrations in different trials were more than twice the expected concentrations from guideline reports.Systematic review registration[https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=215873], identifier [CRD42020215873].

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results